SCHEMBL5405482

SCHEMBL5405482

Cn1c(=O)c2c(-c3cccc(C(=O)O)c3)n(Cc3cccc4ccccc34)nc2n(Cc2cccc(C#N)c2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CFTR P13569 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
DPP4 P27487 2/20 0.38
MMP13 P45452 1/20 0.38
SLC22A8 Q8TCC7 1/20 0.38
SLC16A3 O15427 1/20 0.37
SLC16A1 P53985 1/20 0.37
MCTS1 Q9ULC4 1/20 0.37
HPGD P15428 1/20 0.36
PARG Q86W56 1/20 0.36
ADORA2B P29275 1/20 0.36
POLB P06746 1/20 0.36
HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5398394 0.91 MEN1 (0.52) MEN1KMT2AALDH1A1DPP4MMP13
SCHEMBL5418106 0.89 MAPT (0.47) MEN1KMT2AALDH1A1DPP4HPGD
SCHEMBL5398717 0.89 MEN1 (0.45) MEN1KMT2AHDAC8HDAC6DPP4
SCHEMBL5400336 0.88 MEN1 (0.40) MEN1KMT2AALDH1A1SLC16A1ADORA2B
SCHEMBL5415311 0.87 KMT2A (0.43) MEN1KMT2AALDH1A1DPP4HPGD
SCHEMBL5411110 0.87 MEN1 (0.47) MEN1KMT2AALDH1A1DPP4MMP13
SCHEMBL5410909 0.87 MEN1 (0.47) MEN1KMT2AALDH1A1DPP4
SCHEMBL6677202 0.87 MEN1 (0.44) MEN1KMT2ADPP4SLC16A3SLC16A1
SCHEMBL5402322 0.86 MEN1 (0.45) MEN1KMT2AALDH1A1
SCHEMBL5404381 0.86 MEN1 (0.42) MEN1KMT2AALDH1A1SLC16A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC MEN1 4216/4885KMT2A 3837/4885CFTR 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.